Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Prices Private Placement

NEW YORK, Feb. 10 (GenomeWeb News) - New Haven, Conn.-based CuraGen today announced the pricing of a planned private placement of convertible subordinated notes due in 2011.

The private-placement offering is targeted to raise as much as $100 million, bearing an interest rate of 4 percent, and is due in 2011, the company said in a statement. The notes will convert into 103 shares of the company's common stock for each $1,000 in the principal amount of the notes offered, representing a conversion price of $9.70 per share, subject to adjustment in certain circumstances. The pricing represents a premium of approximately 40 percent above the price of company's stock at the end of the day on Feb. 10. The placement is expected to close on Feb. 17, subject to customary closing conditions, the company said.

Additionally, the company has granted a 30-day option to the initial purchaser of the notes to purchase up to an additional $20 million aggregate principal amount of the notes to cover over-allotments, if any.

The company said it plans to use a portion of the net proceeds to repay its existing debt, and the remainder for working capital, general corporate purposes, and possibly for future acquisitions.

CuraGen has subordinated convertible debt of $150 million due in February of 2007. The company last week reported that it held cash and investments of $343.6 million as of Dec. 31, 2003.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.